CD138, Syndecan-1 (B-A38)Catalogue number: CD138A-1
|Product Type||Monoclonal Antibody|
The antibody B-A38 (like B-B4) stains all plasma cells and all plasma cell lines, which have been tested so far. No other leukocytes are stained in peripheral blood or bone marrow. However, some ALL cell lines express CD138 weekly, and some epithelia and endothelia may be stained in immunohistochemistry. Syndecan 1, CD138, is a heparan-rich glycoprotein (MW 200 kDa), which is expressed on the cell membrane of plasma cells. CD138 functions as a receptor for extracellular matrix proteins like collagen, fibronectin and thrombospondin. Human CD138, Syndecan 1.
Immunogen: U266 cell line
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**and 0.8% BSA . The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.
Purification Method: Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**and 0.8% BSA . The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.
Concentration: 50 µg/ml
Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).
Species Reactivity: Human, others not tested
IHC(C, P), FACS
Incubation Time: 60 min at RT
Working Concentration: (liquid conc.) 1:20-1:100
Pre-Treatment: No protease necessary for IHC, but heat pre-treatment with citrate buffer (Art. No. DE000) or EDTA buffer pH 9 (Art. No. DE006) may enhance staining intensity.
Positive Control: Tonsil
*These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals. ** The preservative sodium azide is known to be poisonous and potentially hazardous to health. It should be handled only by trained staff. Despite of the product's low azide concentration it must be handled with care. Dispose according to regional rules!
1. Borset M., et al. (1993) Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br. J. Haem. 85; 446 ff. 2. Wijdenes J., et al. (1996) A plasmocyte selective monoclonal antibody (B-B4) recognises Syndecan-1. Br. J. Haem. 94; 318-323. 3. Inki. P. and Jalkanen M. (1996) The role of syndecan-1 in malignancies. Ann. Med. 28(1); 63-67. 4. Anttonen A., et al. (1999) Syndecan-1 expression has prognostic significance in head and neck carcinoma. Brit J. Cancer 79; 558-564. 5. Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G,Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J,Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD. (2007) The syndecan-1 heparan sulfate proteoglycan
CD138, Syndecan-1 (B-A38)